Armata Pharmaceuticals, Inc. Common Stock (ARMP)
Armata Pharmaceuticals, Inc. is a biotechnology company focused on developing bacteriophage-based therapies to treat bacterial infections. The company leverages its proprietary platform to create targeted phage products aimed at addressing unmet medical needs, particularly antibiotic-resistant infections. Founded with a focus on innovative approaches to combat bacterial pathogens, Armata aims to offer effective alternatives to traditional antibiotics.
Company News
Armata Pharmaceuticals reported Q2 2025 results with $2.2 million in GAAP revenue, exceeding estimates. The company achieved positive Phase 1b/2a trial results for its AP-SA02 bacteriophage therapy targeting Staphylococcus aureus bacteremia, while managing ongoing financial challenges.
The report forecasts the bronchiectasis treatment market to reach $3.7 billion by 2033, driven by emerging pipeline agents expected to contribute an additional $1.8 billion in sales.
Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -12.50% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Gainers Silicon Motion Technology Corporation (NASDAQ: SIMO) shares climbed 78.9% to $93.40 following a report suggesting China approval of the company's Maxlinear merger. Mallinckrodt plc (NYSE: MNK) gained 70% to $0.75. Sources said Mallinckrodt is considering bankruptcy as part of plan to avoid paying money it owes opioid victims, according ...